Mucke Johanna, Schneider Matthias
Poliklinik, Funktionsbereich und Hiller-Forschungszentrum für Rheumatologie, Heinrich-Heine-Universität Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Deutschland.
Z Rheumatol. 2023 Feb;82(1):40-52. doi: 10.1007/s00393-022-01250-0. Epub 2022 Sep 5.
Lupus nephritis (LN) is one of the most frequent organ manifestations of systemic lupus erythematosus. Urine analysis is suitable for screening and proteinuria or an active sediment with acanthocytes can be indicative for LN. The gold standard for confirming the diagnosis is a kidney biopsy. The type and extent of the histological alterations are decisive for treatment. The LN is histologically classified into six classes, whereby classes III, IV and V in particular require immunosuppressive treatment. The treatment of LN consists of the administration of hydroxychloroquine, angiotensin-converting enzyme (ACE) inhibitors for nephroprotection and further antihypertensive drugs in cases of arterial hypertension. For prognostically unfavorable forms of LN an immunosuppressive treatment is necessary and a variety of substances are available for this. The immunosuppressive treatment is spread over several years, whereby intensive treatment can mostly be de-escalated after 3-6 months. Despite good treatment options the risk of recurrence and also for chronic renal damage with terminal renal failure is elevated and continuous monitoring is absolutely necessary.
狼疮性肾炎(LN)是系统性红斑狼疮最常见的器官表现之一。尿液分析适用于筛查,蛋白尿或伴有棘形红细胞的活动性沉渣可提示LN。确诊的金标准是肾活检。组织学改变的类型和程度对治疗起决定性作用。LN在组织学上分为六类,其中III、IV和V类尤其需要免疫抑制治疗。LN的治疗包括给予羟氯喹、用于肾脏保护的血管紧张素转换酶(ACE)抑制剂以及在动脉高血压情况下使用的其他降压药物。对于预后不良的LN形式,免疫抑制治疗是必要的,有多种药物可用于此。免疫抑制治疗持续数年,强化治疗大多可在3至6个月后逐步降级。尽管有良好的治疗选择,但复发风险以及慢性肾损害导致终末期肾衰竭的风险仍然升高,持续监测绝对必要。